Valneva's Ixchiq is the first and only approved Chikungunya vaccine in the US, Canada, and EU. Ixiaro is for Japanese encephalitis, and it’s today VALN’s main revenue contributor. But its near ...

In November, the U.S. FDA approved Ixchiq as the world’s first chikungunya vaccine. The company reported 28-day and six-month data from the VLA1553-321 trial in 2023 and 2024, respectively.

Ixchiq is now the first vaccine approved in the UK to prevent disease caused by the chikungunya virus (CHIKV) in individuals aged 18 years and older. CHIKV is a mosquito-borne viral disease that ...

French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), ...

Valneva SE, a specialty vaccine company, announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for the world’s ...

Saint Herblain (France), February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory ...

For investors’ note, IXCHIQ is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need. The trial data supports and strengthens the ...

Valneva (NASDAQ:VALN) ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved chikungunya vaccine, Ixchiq, from a Phase 3 trial for ...

Valneva submitted label extension applications to the U.S. Food and Drug Administration FDA , the European Medicines Agency EMA and Health Canada to potentially extend the use of IXCHIQ to ...

The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data, published in The Lancet, which included more than 4,000 participants and demonstrated that a single dose of the live-attenuated ...

The approval is based on IXCHIQ®’s final pivotal Phase 3 data ... We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and ...